Zai Lab Key Executives
This section highlights Zai Lab's key executives, including their titles and compensation details.
Find Contacts at Zai Lab
(Showing 0 of )
Zai Lab Earnings
This section highlights Zai Lab's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | $-0.61 | $-0.80 |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $-0.75 | $-0.42 |
| Read Transcript | Q2 | 2024 | 2024-08-07 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-09 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-02-28 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-11-08 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-08 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-10 | N/A | N/A |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
$31.77
Stock Price
$348.32M
Market Cap
1.87K
Employees
Shanghai, None
Location
Financial Statements
Access annual & quarterly financial statements for Zai Lab, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $398.99M | $266.72M | $215.04M | $144.31M | $48.96M |
| Cost of Revenue | $147.86M | $95.82M | $74.02M | $52.24M | $16.74M |
| Gross Profit | $251.13M | $170.90M | $141.02M | $92.07M | $32.22M |
| Gross Profit Ratio | 62.94% | 64.08% | 65.58% | 63.80% | 65.82% |
| Research and Development Expenses | $234.50M | $265.87M | $286.41M | $573.31M | $222.71M |
| General and Administrative Expenses | $298.74M | $281.61M | $258.97M | $218.83M | $111.31M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $298.74M | $281.61M | $258.97M | $218.83M | $111.31M |
| Other Expenses | $- | $-10.00M | $3.11M | $-5.54M | $29.08M |
| Operating Expenses | $533.25M | $537.48M | $545.38M | $792.14M | $334.02M |
| Cost and Expenses | $681.11M | $633.29M | $619.40M | $844.38M | $350.76M |
| Interest Income | $37.10M | $39.80M | $14.58M | $2.19M | $5.12M |
| Interest Expense | $2.25M | $- | $14.58M | $- | $181.00K |
| Depreciation and Amortization | $11.86M | $9.03M | $8.23M | $6.49M | $4.64M |
| EBITDA | $-242.99M | $-365.11M | $-384.66M | $-689.46M | $-262.96M |
| EBITDA Ratio | -60.90% | -136.89% | -178.88% | -477.76% | -537.12% |
| Operating Income | $-282.12M | $-366.57M | $-404.36M | $-700.06M | $-301.80M |
| Operating Income Ratio | -70.71% | -137.44% | -188.04% | -485.10% | -616.45% |
| Total Other Income Expenses Net | $25.01M | $31.95M | $-38.71M | $-3.35M | $34.02M |
| Income Before Tax | $-257.10M | $-334.62M | $-443.06M | $-703.41M | $-267.79M |
| Income Before Tax Ratio | -64.44% | -125.46% | -206.04% | -487.43% | -546.97% |
| Income Tax Expense | $- | $- | $38.93M | $-10.97M | $30.38M |
| Net Income | $-257.10M | $-334.62M | $-481.99M | $-692.44M | $-298.16M |
| Net Income Ratio | -64.44% | -125.46% | -224.14% | -479.82% | -609.02% |
| EPS | $-2.60 | $-3.46 | $-4.63 | $-7.58 | $-3.46 |
| EPS Diluted | $-0.26 | $-3.46 | $-4.63 | $-7.58 | $-3.46 |
| Weighted Average Shares Outstanding | 98.95M | 96.64M | 95.81M | 92.99M | 77.67M |
| Weighted Average Shares Outstanding Diluted | 989.48M | 96.64M | 95.81M | 92.99M | 77.67M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.07M | $102.27M | $100.50M | $87.15M | $65.83M | $69.23M | $68.86M | $62.80M | $62.60M | $57.54M | $48.18M | $46.72M | $44.17M | $43.10M | $36.94M | $20.10M | $15.09M | $14.65M | $10.99M | $8.22M |
| Cost of Revenue | $42.09M | $36.92M | $35.23M | $33.62M | $25.24M | $25.48M | $23.76M | $21.34M | $20.92M | $20.04M | $17.41M | $15.64M | $21.70M | $12.16M | $10.87M | $7.50M | $6.82M | $4.93M | $2.90M | $2.08M |
| Gross Profit | $66.98M | $65.35M | $65.27M | $53.53M | $40.59M | $43.75M | $45.10M | $41.46M | $41.68M | $37.50M | $30.77M | $31.08M | $22.47M | $30.94M | $26.07M | $12.60M | $8.27M | $9.72M | $8.10M | $6.13M |
| Gross Profit Ratio | 61.41% | 63.90% | 64.94% | 61.42% | 61.66% | 63.20% | 65.49% | 66.02% | 66.58% | 65.17% | 63.87% | 66.52% | 50.86% | 71.78% | 70.58% | 62.67% | 54.80% | 66.32% | 73.66% | 74.64% |
| Research and Development Expenses | $52.25M | $65.98M | $61.62M | $54.65M | $81.95M | $58.77M | $76.68M | $48.47M | $66.95M | $99.52M | $66.08M | $53.85M | $172.09M | $55.14M | $142.22M | $203.85M | $62.56M | $58.10M | $68.31M | $33.74M |
| General and Administrative Expenses | $82.62M | $67.22M | $79.71M | $69.19M | $82.63M | $68.55M | $67.92M | $62.51M | $72.02M | $66.56M | $63.40M | $56.99M | $69.58M | $59.00M | $54.41M | $35.84M | $40.97M | $27.87M | $23.76M | $18.71M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $82.62M | $67.22M | $79.71M | $69.19M | $82.63M | $68.55M | $67.92M | $62.51M | $72.02M | $66.56M | $63.40M | $56.99M | $69.58M | $59.00M | $54.41M | $35.84M | $40.97M | $27.87M | $23.76M | $18.71M |
| Other Expenses | $- | $- | $- | $9.36M | $1.56M | $394.00K | $-1.41M | $1.23M | $82.58M | $-36.48M | $-40.39M | $-2.60M | $6.86M | $-13.58M | $7.41M | $-6.23M | $17.81M | $11.96M | $2.43M | $-3.12M |
| Operating Expenses | $134.87M | $133.20M | $172.32M | $123.84M | $162.14M | $127.32M | $144.60M | $110.98M | $138.97M | $166.08M | $129.49M | $110.84M | $241.66M | $114.15M | $196.64M | $239.69M | $103.53M | $85.97M | $92.06M | $52.46M |
| Cost and Expenses | $176.96M | $170.12M | $176.57M | $157.46M | $187.38M | $152.80M | $168.37M | $132.32M | $159.89M | $186.12M | $146.89M | $126.49M | $263.37M | $126.31M | $207.51M | $247.19M | $110.35M | $90.91M | $94.96M | $54.54M |
| Interest Income | $9.09M | $9.03M | $9.33M | $9.66M | $10.30M | $9.17M | $10.09M | $10.23M | $9.35M | $3.87M | $1.18M | $188.00K | $1.02M | $713.00K | $244.00K | $214.00K | $1.37M | $866.00K | $1.23M | $1.66M |
| Interest Expense | $904.00K | $745.00K | $492.00K | $113.00K | $- | $- | $- | $- | $9.35M | $3.87M | $1.18M | $188.00K | $- | $- | $- | $- | $24.00K | $43.00K | $55.00K | $59.00K |
| Depreciation and Amortization | $3.03M | $2.87M | $2.94M | $3.01M | $2.46M | $1.92M | $2.00M | $2.66M | $2.13M | $2.23M | $1.86M | $2.01M | $1.88M | $1.64M | $1.53M | $1.45M | $1.39M | $1.15M | $1.04M | $1.07M |
| EBITDA | $-77.75M | $-38.05M | $-76.84M | $-50.35M | $-119.09M | $-81.65M | $-118.90M | $-46.49M | $-133.87M | $-126.36M | $-96.86M | $-77.75M | $-209.44M | $-81.57M | $-169.04M | $-225.64M | $-74.69M | $-62.29M | $-79.27M | $-46.72M |
| EBITDA Ratio | -71.28% | -37.21% | -76.46% | -57.77% | -180.90% | -117.95% | -172.66% | -74.03% | -213.85% | -219.60% | -201.04% | -166.40% | -474.16% | -189.24% | -457.68% | -1122.44% | -494.82% | -425.14% | -720.95% | -568.53% |
| Operating Income | $-67.89M | $-67.85M | $-76.06M | $-70.31M | $-123.98M | $-83.57M | $-89.50M | $-69.52M | $-97.29M | $-128.58M | $-98.72M | $-79.76M | $-219.20M | $-83.20M | $-170.57M | $-227.09M | $-95.26M | $-76.26M | $-83.97M | $-46.32M |
| Operating Income Ratio | -62.25% | -66.35% | -75.68% | -80.68% | -188.34% | -120.72% | -129.97% | -110.71% | -155.42% | -223.47% | -204.91% | -170.71% | -496.24% | -193.04% | -461.81% | -1129.64% | -631.09% | -520.49% | -763.67% | -563.67% |
| Total Other Income Expenses Net | $-13.79M | $26.18M | $-4.21M | $16.84M | $28.55M | $14.42M | $-31.39M | $20.38M | $35.52M | $-32.61M | $-39.22M | $-2.41M | $7.88M | $-12.87M | $7.65M | $-6.01M | $19.16M | $12.78M | $3.61M | $-1.53M |
| Income Before Tax | $-81.68M | $-41.67M | $-80.28M | $-53.47M | $-95.43M | $-69.15M | $-120.89M | $-49.14M | $-61.77M | $-161.19M | $-137.93M | $-82.17M | $-211.32M | $-96.07M | $-162.92M | $-233.10M | $-76.10M | $-63.48M | $-80.36M | $-47.85M |
| Income Before Tax Ratio | -74.89% | -40.75% | -79.87% | -61.36% | -144.96% | -99.89% | -175.56% | -78.26% | -98.67% | -280.14% | -286.31% | -175.87% | -478.40% | -222.89% | -441.10% | -1159.55% | -504.17% | -433.25% | -730.88% | -582.27% |
| Income Tax Expense | $- | $- | $- | $9.47M | $-21.77M | $-9.17M | $17.99M | $-31.95M | $-35.52M | $32.61M | $39.22M | $2.63M | $7.37M | $-14.88M | $7.81M | $-6.42M | $18.28M | $12.27M | $2.76M | $-2.93M |
| Net Income | $-81.68M | $-41.67M | $-80.28M | $-53.47M | $-95.43M | $-69.15M | $-120.89M | $-17.20M | $-26.25M | $-193.80M | $-177.15M | $-84.80M | $-211.82M | $-96.41M | $-163.32M | $-232.91M | $-76.55M | $-63.74M | $-80.63M | $-47.99M |
| Net Income Ratio | -74.89% | -40.75% | -79.87% | -61.36% | -144.96% | -99.89% | -175.56% | -27.39% | -41.92% | -336.80% | -367.71% | -181.50% | -479.56% | -223.68% | -442.19% | -1158.58% | -507.14% | -435.06% | -733.32% | -583.94% |
| EPS | $-0.80 | $-0.43 | $-0.82 | $-0.55 | $-0.98 | $-0.71 | $-1.25 | $-0.51 | $-0.64 | $-1.68 | $-1.44 | $-0.86 | $-2.22 | $-1.01 | $-1.76 | $-2.64 | $-0.87 | $-0.84 | $-1.08 | $-0.66 |
| EPS Diluted | $-0.08 | $-0.43 | $-0.82 | $-0.55 | $-0.98 | $-0.71 | $-1.25 | $-0.51 | $-0.64 | $-1.68 | $-1.44 | $-0.86 | $-2.22 | $-1.01 | $-1.76 | $-2.64 | $-0.87 | $-0.84 | $-1.08 | $-0.66 |
| Weighted Average Shares Outstanding | 102.68M | 97.59M | 97.59M | 97.31M | 97.04M | 96.88M | 96.48M | 96.14M | 95.99M | 95.91M | 95.77M | 95.55M | 95.44M | 95.04M | 93.05M | 88.37M | 87.53M | 75.44M | 74.74M | 72.96M |
| Weighted Average Shares Outstanding Diluted | 1.03B | 97.59M | 97.59M | 97.31M | 97.04M | 96.88M | 96.48M | 96.14M | 95.99M | 95.91M | 95.77M | 95.55M | 95.44M | 95.04M | 93.05M | 88.37M | 87.53M | 75.44M | 74.74M | 72.96M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $449.67M | $790.15M | $1.01B | $964.10M | $442.12M |
| Short Term Investments | $330.00M | $16.30M | $- | $445.00M | $744.68M |
| Cash and Short Term Investments | $779.67M | $806.45M | $1.01B | $1.41B | $1.19B |
| Net Receivables | $89.41M | $65.33M | $48.57M | $54.81M | $5.17M |
| Inventory | $39.88M | $44.83M | $31.62M | $18.95M | $13.14M |
| Other Current Assets | $141.53M | $23.00M | $35.67M | $18.02M | $10.94M |
| Total Current Assets | $1.05B | $939.61M | $1.12B | $1.50B | $1.22B |
| Property Plant Equipment Net | $69.47M | $68.69M | $78.77M | $58.28M | $47.14M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $58.93M | $16.46M | $8.40M | $9.66M | $9.44M |
| Goodwill and Intangible Assets | $58.93M | $16.46M | $8.40M | $9.66M | $9.44M |
| Long Term Investments | $3.12M | $9.22M | $6.43M | $15.61M | $1.28M |
| Tax Assets | $- | $1 | $- | $24.73M | $23.00M |
| Other Non-Current Assets | $3.75M | $2.32M | $2.20M | $803.00K | $743.00K |
| Total Non-Current Assets | $135.27M | $96.69M | $95.80M | $109.08M | $81.60M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.19B | $1.04B | $1.22B | $1.61B | $1.30B |
| Account Payables | $100.91M | $112.99M | $65.97M | $126.16M | $62.64M |
| Short Term Debt | $139.76M | $7.10M | $7.05M | $5.93M | $5.21M |
| Tax Payables | $5.15M | $16.99M | $13.28M | $8.82M | $952.00K |
| Deferred Revenue | $- | $- | $- | $- | $24.75M |
| Other Current Liabilities | $53.57M | $65.98M | $53.53M | $51.99M | $29.24M |
| Total Current Liabilities | $299.38M | $203.07M | $139.84M | $192.90M | $98.04M |
| Long Term Debt | $13.71M | $8.05M | $13.34M | $9.61M | $13.39M |
| Deferred Revenue Non-Current | $31.43M | $- | $21.36M | $27.49M | $16.86M |
| Deferred Tax Liabilities Non-Current | $- | $- | $-21.36M | $-27.49M | $-16.86M |
| Other Non-Current Liabilities | $325.00K | $29.06M | $- | $- | $- |
| Total Non-Current Liabilities | $45.47M | $37.11M | $34.70M | $37.10M | $30.25M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $344.86M | $240.18M | $174.54M | $230.00M | $128.29M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $7.00K | $6.00K | $6.00K | $6.00K | $5.00K |
| Retained Earnings | $-2.45B | $-2.20B | $-1.86B | $-1.42B | $-713.60M |
| Accumulated Other Comprehensive Income Loss | $50.52M | $37.63M | $25.68M | $-23.64M | $-14.52M |
| Other Total Stockholders Equity | $3.24B | $2.95B | $2.88B | $2.82B | $1.90B |
| Total Stockholders Equity | $840.90M | $796.12M | $1.05B | $1.38B | $1.17B |
| Total Equity | $840.90M | $796.12M | $1.05B | $1.38B | $1.17B |
| Total Liabilities and Stockholders Equity | $1.19B | $1.04B | $1.22B | $1.61B | $1.30B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.19B | $1.04B | $1.22B | $1.61B | $1.30B |
| Total Investments | $333.12M | $25.52M | $6.43M | $460.61M | $745.96M |
| Total Debt | $153.47M | $15.15M | $20.39M | $15.54M | $18.60M |
| Net Debt | $-296.20M | $-775.00M | $-988.08M | $-948.56M | $-423.52M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $449.67M | $616.09M | $630.05M | $650.78M | $790.15M | $788.81M | $859.15M | $879.84M | $1.01B | $1.12B | $680.82M | $846.96M | $964.10M | $1.40B | $1.77B | $1.01B | $442.12M | $258.60M | $-275.93M | $75.93M |
| Short Term Investments | $330.00M | $- | $- | $- | $16.30M | $31.60M | $15.50M | $50.55M | $- | $- | $575.27M | $465.27M | $445.00M | $170.00M | $- | $- | $744.68M | $205.00M | $551.86M | $200.00M |
| Cash and Short Term Investments | $779.67M | $616.09M | $630.05M | $650.78M | $806.45M | $820.41M | $874.65M | $930.39M | $1.01B | $1.12B | $1.26B | $1.31B | $1.41B | $1.57B | $1.77B | $1.01B | $1.19B | $463.60M | $275.93M | $275.93M |
| Net Receivables | $89.41M | $69.25M | $77.74M | $75.78M | $65.33M | $65.28M | $68.06M | $60.73M | $48.57M | $39.07M | $38.24M | $44.24M | $54.81M | $21.02M | $18.03M | $8.81M | $5.17M | $7.02M | $- | $3.79M |
| Inventory | $39.88M | $39.55M | $41.85M | $37.85M | $44.83M | $44.23M | $36.35M | $38.41M | $31.62M | $29.13M | $23.34M | $20.29M | $18.95M | $12.49M | $11.11M | $12.63M | $13.14M | $6.57M | $- | $6.00M |
| Other Current Assets | $141.53M | $135.67M | $120.29M | $124.22M | $23.00M | $29.82M | $38.43M | $42.77M | $35.67M | $- | $- | $16.49M | $18.02M | $17.08M | $12.89M | $14.32M | $10.94M | $7.68M | $- | $- |
| Total Current Assets | $1.05B | $860.55M | $869.92M | $888.64M | $939.61M | $959.73M | $1.02B | $1.07B | $1.12B | $1.21B | $1.34B | $1.39B | $1.50B | $1.62B | $1.81B | $1.05B | $1.22B | $484.88M | $275.93M | $292.46M |
| Property Plant Equipment Net | $69.47M | $63.63M | $63.72M | $67.66M | $68.69M | $71.82M | $75.61M | $80.18M | $78.77M | $74.86M | $69.56M | $67.19M | $58.28M | $53.73M | $50.50M | $45.91M | $47.14M | $35.33M | $- | $44.08M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-7.66M |
| Intangible Assets | $58.93M | $54.68M | $47.05M | $15.43M | $16.46M | $4.62M | $4.76M | $8.40M | $8.40M | $8.36M | $8.96M | $9.52M | $9.66M | $9.43M | $9.58M | $9.37M | $9.44M | $8.63M | $- | $8.80M |
| Goodwill and Intangible Assets | $58.93M | $54.68M | $47.05M | $15.43M | $16.46M | $4.62M | $4.76M | $8.40M | $8.40M | $8.36M | $8.96M | $9.52M | $9.66M | $9.43M | $9.58M | $9.37M | $9.44M | $8.63M | $- | $1.15M |
| Long Term Investments | $3.12M | $3.15M | $4.07M | $14.11M | $9.22M | $4.47M | $5.13M | $6.87M | $6.43M | $3.32M | $2.83M | $8.44M | $15.61M | $20.80M | $1.07M | $1.47M | $1.28M | $1.99M | $- | $2.40M |
| Tax Assets | $- | $- | $1.44M | $1.48M | $1.21M | $1.26M | $1.58M | $- | $- | $- | $- | $- | $24.73M | $24.29M | $24.71M | $24.61M | $23.00M | $16.87M | $- | $14.55M |
| Other Non-Current Assets | $3.75M | $3.33M | $1.16M | $1.11M | $1.11M | $1.79M | $1.79M | $2.33M | $2.20M | $2.14M | $1.79M | $22.51M | $803.00K | $743.00K | $743.00K | $743.00K | $743.00K | $510.00K | $-275.93M | $510.22K |
| Total Non-Current Assets | $135.27M | $124.80M | $117.44M | $99.80M | $96.69M | $83.96M | $88.87M | $97.78M | $95.80M | $88.68M | $83.13M | $107.66M | $109.08M | $108.99M | $86.61M | $82.11M | $81.60M | $63.33M | $-275.93M | $62.69M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.19B | $985.35M | $987.37M | $988.44M | $1.04B | $1.04B | $1.11B | $1.17B | $1.22B | $1.30B | $1.42B | $1.50B | $1.61B | $1.73B | $1.90B | $1.13B | $1.30B | $548.21M | $- | $355.15M |
| Account Payables | $100.91M | $120.65M | $127.34M | $88.12M | $112.99M | $55.02M | $67.03M | $66.36M | $65.97M | $90.11M | $108.44M | $98.16M | $126.16M | $51.41M | $125.62M | $41.41M | $62.64M | $32.39M | $- | $22.66M |
| Short Term Debt | $139.76M | $119.58M | $77.88M | $55.81M | $7.10M | $6.89M | $7.30M | $7.32M | $7.05M | $6.98M | $6.82M | $6.79M | $5.93M | $6.31M | $6.37M | $5.60M | $5.21M | $8.41M | $- | $10.80M |
| Tax Payables | $5.15M | $3.76M | $4.62M | $6.91M | $16.99M | $13.79M | $15.77M | $13.00M | $13.28M | $10.40M | $9.90M | $9.93M | $8.82M | $10.99M | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $45.38M | $77.62M | $- | $- | $- | $- | $- | $- | $- | $56.39M | $- | $46.22M | $3.28M | $24.75M | $10.83M | $- | $- |
| Other Current Liabilities | $53.57M | $42.33M | $41.87M | $41.27M | $65.98M | $49.20M | $43.26M | $37.88M | $53.53M | $48.05M | $43.71M | $40.02M | $51.99M | $43.30M | $61.92M | $45.64M | $30.20M | $15.75M | $- | $13.17M |
| Total Current Liabilities | $299.38M | $286.31M | $251.72M | $192.11M | $203.07M | $124.90M | $133.35M | $124.56M | $139.84M | $155.55M | $168.88M | $154.91M | $192.90M | $112.01M | $193.92M | $92.66M | $98.04M | $56.55M | $- | $46.64M |
| Long Term Debt | $13.71M | $6.11M | $5.80M | $7.54M | $8.05M | $9.81M | $11.76M | $12.98M | $13.34M | $13.89M | $12.96M | $11.10M | $9.61M | $10.65M | $11.97M | $12.31M | $13.39M | $10.46M | $- | $10.98M |
| Deferred Revenue Non-Current | $31.43M | $24.92M | $- | $26.30M | $28.74M | $27.69M | $28.62M | $30.97M | $21.36M | $23.20M | $24.77M | $26.90M | $27.49M | $17.49M | $17.63M | $16.66M | $16.86M | $15.74M | $- | $2.88M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $-21.36M | $-23.20M | $-24.77M | $-26.90M | $-27.49M | $-17.49M | $-17.63M | $-12.31M | $-13.39M | $-10.46M | $- | $-10.98M |
| Other Non-Current Liabilities | $325.00K | $325.00K | $25.67M | $26.62M | $29.06M | $28.01M | $28.95M | $31.29M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $197 |
| Total Non-Current Liabilities | $45.47M | $31.36M | $31.47M | $34.16M | $37.11M | $37.82M | $40.70M | $44.27M | $34.70M | $37.10M | $37.73M | $37.99M | $37.10M | $28.14M | $29.60M | $28.96M | $30.25M | $26.19M | $- | $13.86M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $344.86M | $317.68M | $283.19M | $226.27M | $240.18M | $162.72M | $174.06M | $168.83M | $174.54M | $192.65M | $206.61M | $192.91M | $230.00M | $140.15M | $223.52M | $121.62M | $128.29M | $82.75M | $- | $60.49M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $7.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $5.00K | $5.00K | $4.00K | $- | $4.09K |
| Retained Earnings | $-2.45B | $-2.37B | $-2.33B | $-2.25B | $-2.20B | $-2.10B | $-2.03B | $-1.91B | $-1.86B | $-1.80B | $-1.64B | $-1.50B | $-1.42B | $-1.21B | $-1.11B | $-946.51M | $-713.60M | $-573.32M | $- | $-444.70M |
| Accumulated Other Comprehensive Income Loss | $50.52M | $28.27M | $42.77M | $39.17M | $37.63M | $47.95M | $52.18M | $17.27M | $25.68M | $39.55M | $4.49M | $-25.84M | $-23.64M | $-15.12M | $-16.86M | $-11.62M | $-14.52M | $6.99M | $294.66M | $4.62M |
| Other Total Stockholders Equity | $3.24B | $3.01B | $2.99B | $2.97B | $2.95B | $2.93B | $2.91B | $2.89B | $2.88B | $2.87B | $2.85B | $2.83B | $2.82B | $2.81B | $2.80B | $1.97B | $1.90B | $1.03B | $- | $734.73M |
| Total Stockholders Equity | $840.90M | $667.67M | $704.18M | $762.17M | $796.12M | $880.98M | $932.31M | $1.00B | $1.05B | $1.11B | $1.21B | $1.31B | $1.38B | $1.59B | $1.67B | $1.01B | $1.17B | $465.47M | $294.66M | $294.66M |
| Total Equity | $840.90M | $667.67M | $704.18M | $762.17M | $796.12M | $880.98M | $932.31M | $1.00B | $1.05B | $1.11B | $1.21B | $1.31B | $1.38B | $1.59B | $1.67B | $1.01B | $1.17B | $465.47M | $294.66M | $294.66M |
| Total Liabilities and Stockholders Equity | $1.19B | $985.35M | $987.37M | $988.44M | $1.04B | $1.04B | $1.11B | $1.17B | $1.22B | $1.30B | $1.42B | $1.50B | $1.61B | $1.73B | $1.90B | $1.13B | $1.30B | $548.21M | $294.66M | $355.15M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.19B | $985.35M | $987.37M | $988.44M | $1.04B | $1.04B | $1.11B | $1.17B | $1.22B | $1.30B | $1.42B | $1.50B | $1.61B | $1.73B | $1.90B | $1.13B | $1.30B | $548.21M | $294.66M | $355.15M |
| Total Investments | $333.12M | $3.15M | $4.07M | $14.11M | $25.52M | $36.07M | $20.63M | $57.42M | $6.43M | $3.32M | $578.10M | $473.72M | $460.61M | $190.80M | $1.07M | $1.47M | $745.96M | $206.99M | $551.86M | $202.40M |
| Total Debt | $153.47M | $125.69M | $83.68M | $63.35M | $15.15M | $16.69M | $19.05M | $20.30M | $20.39M | $20.87M | $19.78M | $17.89M | $15.54M | $16.96M | $18.34M | $17.91M | $18.60M | $18.87M | $- | $21.78M |
| Net Debt | $-296.20M | $-490.39M | $-546.37M | $-587.43M | $-775.00M | $-772.11M | $-840.10M | $-859.55M | $-988.08M | $-1.10B | $-661.04M | $-829.06M | $-948.56M | $-1.38B | $-1.75B | $-995.51M | $-423.52M | $-239.73M | $275.93M | $-54.15M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-257.10M | $-334.62M | $-443.29M | $-704.47M | $-268.90M |
| Depreciation and Amortization | $11.86M | $9.03M | $8.23M | $6.49M | $4.64M |
| Deferred Income Tax | $- | $- | $- | $17.08M | $1.13M |
| Stock Based Compensation | $70.65M | $79.63M | $61.30M | $40.71M | $24.83M |
| Change in Working Capital | $-68.39M | $39.61M | $-66.25M | $23.11M | $18.25M |
| Accounts Receivables | $-26.58M | $-20.04M | $4.33M | $-42.32M | $-1.38M |
| Inventory | $3.90M | $-14.91M | $-15.38M | $-7.17M | $-7.17M |
| Accounts Payables | $-2.21M | $36.80M | $-53.77M | $63.52M | $39.98M |
| Other Working Capital | $-43.50M | $37.75M | $-1.42M | $9.08M | $-13.19M |
| Other Non Cash Items | $28.12M | $8.17M | $72.36M | $67.85M | $4.01M |
| Net Cash Provided by Operating Activities | $-214.87M | $-198.18M | $-367.64M | $-549.23M | $-216.06M |
| Investments in Property Plant and Equipment | $-5.66M | $-7.21M | $-24.98M | $-18.95M | $-10.67M |
| Acquisitions Net | $- | $- | $-444.60M | $-30.00M | $539.00K |
| Purchases of Investments | $-330.00M | $-134.00M | $-260.27M | $-445.00M | $-949.16M |
| Sales Maturities of Investments | $16.30M | $117.70M | $705.27M | $743.90M | $405.00M |
| Other Investing Activities | $-55.84M | $12.74M | $444.60M | $3.00K | $-539.00K |
| Net Cash Used for Investing Activities | $-375.19M | $-10.78M | $420.02M | $249.96M | $-554.83M |
| Debt Repayment | $131.32M | $- | $- | $- | $- |
| Common Stock Issued | $217.35M | $- | $- | $818.88M | $1.14B |
| Common Stock Repurchased | $- | $-8.80M | $-7.60M | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.22M | $-6.43M | $5.87M | $1.33M | $-5.24M |
| Net Cash Used Provided by Financing Activities | $349.89M | $-6.43M | $-1.73M | $820.20M | $1.13B |
| Effect of Forex Changes on Cash | $-310.00K | $-2.62M | $-6.27M | $1.12M | $4.86M |
| Net Change in Cash | $-240.48M | $-218.01M | $44.37M | $522.04M | $366.42M |
| Cash at End of Period | $550.78M | $791.26M | $1.01B | $964.90M | $442.86M |
| Cash at Beginning of Period | $791.26M | $1.01B | $964.90M | $442.86M | $76.44M |
| Operating Cash Flow | $-214.87M | $-198.18M | $-367.64M | $-549.23M | $-216.06M |
| Capital Expenditure | $-61.52M | $-8.49M | $-24.98M | $-18.95M | $-10.67M |
| Free Cash Flow | $-276.39M | $-206.67M | $-392.63M | $-568.18M | $-226.72M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-81.68M | $-41.67M | $-80.28M | $-53.47M | $-95.43M | $-69.15M | $-120.89M | $-49.14M | $-61.77M | $-161.19M | $-137.93M | $-82.39M | $-211.82M | $-96.41M | $-163.32M | $-232.91M | $-76.55M | $-63.74M | $-80.63M | $-47.99M |
| Depreciation and Amortization | $3.03M | $2.87M | $2.94M | $3.01M | $2.46M | $1.92M | $2.00M | $2.66M | $2.13M | $2.23M | $1.86M | $2.01M | $1.88M | $1.64M | $1.53M | $1.45M | $1.39M | $1.15M | $1.04M | $1.07M |
| Deferred Income Tax | $- | $- | $- | $- | $-15.91M | $-4.20M | $31.86M | $- | $- | $- | $- | $- | $6.18M | $10.39M | $682.00K | $-176.00K | $454.00K | $258.00K | $278.00K | $138.00K |
| Stock Based Compensation | $17.24M | $16.80M | $18.64M | $17.98M | $20.47M | $21.99M | $20.51M | $16.66M | $15.56M | $19.11M | $14.22M | $12.41M | $12.61M | $10.56M | $10.23M | $7.32M | $4.42M | $6.98M | $6.96M | $6.46M |
| Change in Working Capital | $-19.14M | $7.54M | $384.00K | $-57.18M | $72.25M | $-7.25M | $7.04M | $-32.43M | $-47.99M | $-60.66M | $70.15M | $-27.75M | $36.93M | $-88.80M | $83.66M | $-8.67M | $24.96M | $-25.10M | $18.90M | $-508.00K |
| Accounts Receivables | $-22.17M | $8.44M | $-9.51M | $-1.33M | $-17.22M | $6.04M | $-6.01M | $-2.85M | $-12.15M | $-3.94M | $6.34M | $14.08M | $-26.46M | $-2.99M | $-9.22M | $-3.65M | $2.33M | $-469.00K | $-2.94M | $-296.00K |
| Inventory | $-507.00K | $2.37M | $-4.78M | $6.82M | $-499.00K | $-7.78M | $59.00K | $-6.69M | $-2.15M | $-8.65M | $-3.11M | $-1.48M | $-7.42M | $-1.49M | $1.24M | $502.00K | $-3.54M | $-3.06M | $-526.00K | $-45.00K |
| Accounts Payables | $-8.75M | $12.66M | $7.25M | $-13.37M | $46.30M | $-12.53M | $3.36M | $-327.00K | $-24.92M | $-11.13M | $10.28M | $-28.00M | $74.76M | $-74.22M | $84.21M | $-21.23M | $34.76M | $-4.51M | $5.24M | $4.50M |
| Other Working Capital | $12.29M | $-15.93M | $7.43M | $-1.55M | $43.67M | $7.02M | $9.63M | $-22.57M | $-8.76M | $-36.93M | $56.63M | $-12.35M | $-3.95M | $-10.10M | $7.43M | $15.70M | $-8.60M | $-17.06M | $17.13M | $-4.66M |
| Other Non Cash Items | $24.78M | $-12.36M | $16.14M | $1.93M | $1.24M | $1.42M | $785.00K | $-7.03M | $-17.22M | $74.19M | $6.80M | $8.60M | $1.24M | $1.74M | $1.38M | $63.49M | $989.00K | $1.06M | $974.00K | $984.00K |
| Net Cash Provided by Operating Activities | $-55.77M | $-26.82M | $-42.17M | $-90.11M | $-14.92M | $-55.27M | $-58.70M | $-69.29M | $-109.29M | $-126.32M | $-44.90M | $-87.13M | $-152.99M | $-160.89M | $-65.85M | $-169.50M | $-44.34M | $-79.40M | $-52.48M | $-39.84M |
| Investments in Property Plant and Equipment | $-2.60M | $-1.34M | $-741.00K | $-13.01M | $-843.00K | $-1.78M | $-2.35M | $-3.52M | $-4.37M | $-7.02M | $-3.70M | $-9.89M | $-6.49M | $-6.38M | $-4.18M | $-1.90M | $-5.46M | $-3.68M | $-473.00K | $-1.05M |
| Acquisitions Net | $- | $- | $- | $- | $- | $28.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $169.00K | $152.00K | $- | $- |
| Purchases of Investments | $-330.00M | $- | $- | $- | $- | $-34.00M | $- | $-100.00M | $- | $- | $-140.00M | $-120.27M | $-275.00M | $-170.00M | $- | $- | $-199.49M | $-544.68M | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $16.30M | $15.30M | $17.90M | $35.05M | $49.45M | $- | $575.27M | $30.00M | $100.00M | $- | $- | $- | $743.90M | $405.00M | $-200.00M | $150.00M | $50.00M |
| Other Investing Activities | $-15.15M | $-28.54M | $-105.00K | $4.27M | $14.68M | $3.88M | $10.00M | $112.00K | $40.00K | $574.94M | $-25.00K | $25.00K | $-275.11M | $-30.00M | $-213.00K | $743.69M | $-169.00K | $-152.00K | $-205.00M | $49.99M |
| Net Cash Used for Investing Activities | $-347.75M | $-29.89M | $-846.00K | $3.29M | $14.46M | $-13.98M | $42.70M | $-53.95M | $-4.37M | $568.26M | $-113.72M | $-30.14M | $-281.49M | $-206.38M | $-4.18M | $742.00M | $200.05M | $-748.36M | $-55.47M | $48.95M |
| Debt Repayment | $19.87M | $40.93M | $22.28M | $48.25M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00K | $- | $818.87M | $- | $111.71M | $744.67M | $- | $281.30M |
| Common Stock Repurchased | $- | $- | $- | $- | $-77.00K | $-1.58M | $-2.06M | $-5.08M | $-429.00K | $-312.00K | $-6.82M | $-39.00K | $- | $-2.87M | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $217.95M | $1.28M | $44.00K | $-700.00K | $393.00K | $-1.45M | $565.00K | $1.20M | $230.00K | $709.00K | $-2.50M | $258.00K | $-277.00K | $-471.00K | $2.35M | $-271.00K | $-3.76M | $-1.69M | $2.02M | $-1.81M |
| Net Cash Used Provided by Financing Activities | $237.81M | $42.21M | $22.32M | $47.55M | $393.00K | $-1.45M | $-1.49M | $-3.89M | $-199.00K | $709.00K | $-2.50M | $258.00K | $-276.00K | $-471.00K | $821.22M | $-271.00K | $107.95M | $742.99M | $2.02M | $279.48M |
| Effect of Forex Changes on Cash | $-712.00K | $539.00K | $-33.00K | $-104.00K | $733.00K | $352.00K | $-2.41M | $-1.30M | $2.86M | $-3.99M | $-5.01M | $-130.00K | $421.00K | $-333.00K | $1.96M | $-930.00K | $2.80M | $2.05M | $959.00K | $-947.00K |
| Net Change in Cash | $-166.42M | $-13.96M | $-20.73M | $-39.37M | $666.00K | $-70.35M | $-19.90M | $-128.43M | $-111.01M | $438.66M | $-166.14M | $-117.14M | $-434.34M | $-368.07M | $753.15M | $571.30M | $266.47M | $-82.72M | $-104.98M | $287.65M |
| Cash at End of Period | $550.78M | $717.20M | $731.16M | $751.89M | $791.26M | $790.60M | $860.95M | $880.85M | $1.01B | $1.12B | $681.62M | $847.76M | $964.90M | $1.40B | $1.77B | $1.01B | $442.86M | $176.39M | $259.11M | $364.09M |
| Cash at Beginning of Period | $717.20M | $731.16M | $751.89M | $791.26M | $790.60M | $860.95M | $880.85M | $1.01B | $1.12B | $681.62M | $847.76M | $964.90M | $1.40B | $1.77B | $1.01B | $442.86M | $176.39M | $259.11M | $364.09M | $76.44M |
| Operating Cash Flow | $-55.77M | $-26.82M | $-42.17M | $-90.11M | $-14.92M | $-55.27M | $-58.70M | $-69.29M | $-109.29M | $-126.32M | $-44.90M | $-87.13M | $-152.99M | $-160.89M | $-65.85M | $-169.50M | $-44.34M | $-79.40M | $-52.48M | $-39.84M |
| Capital Expenditure | $-17.75M | $-29.89M | $-875.00K | $-13.01M | $-843.00K | $-1.78M | $-2.35M | $-3.52M | $-4.37M | $-7.02M | $-3.70M | $-9.89M | $-6.49M | $-6.38M | $-4.18M | $-1.90M | $-5.46M | $-3.68M | $-473.00K | $-1.05M |
| Free Cash Flow | $-73.52M | $-56.71M | $-43.05M | $-103.11M | $-15.76M | $-57.06M | $-61.05M | $-72.80M | $-113.67M | $-133.34M | $-48.60M | $-97.02M | $-159.48M | $-167.27M | $-70.03M | $-171.40M | $-49.80M | $-83.08M | $-52.95M | $-40.89M |
Zai Lab Dividends
Explore Zai Lab's dividend history, including dividend yield, payout ratio, and historical payments.
Zai Lab News
Read the latest news about Zai Lab, including recent articles, headlines, and updates.
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company's internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research.
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year, driven by strong revenue growth and ambitious plans for future drug launches. The company aims to achieve $2bn in annual revenues by 2028, with key drugs like Vyvgart and Cobenfy leading the charge.
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China.
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. “In China, cervical cancer is a serious health concern with approximately 150,000 new cases diagnosed annually1,”.
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet
The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zai Lab Announces Participation in Investor Conferences in March 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in March 2025: Leerink Partners 2025 Global Healthcare Conference Fireside Chat: Monday, March 10, 2025, 9:20 a.m. EST Location: Miami, FL Jefferies Biotech on the Beach Summit Time: Tuesday, March 11, 2025 Location: Miami, FL A live webcast of the fireside chat will be available on th.
Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Head of Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Michael Yee - Jefferies Yen-Der Li - Leerink Partners Reena Patel - Citi Linhai Zhao - Goldman Sachs Li Wang Watsek - Cantor Fitzgerald Po Han Lin - Morgan Stanley Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to Zai Lab's Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights and corporate updates. “2024 was a defining year for Zai Lab, marked by strong sales growth, financial strength, and significant pipeline progress. As we look ahead, 2025 is set to be a transformative year with VYVGART's continued momentum, three new product launches, progress with ZL-1310, and.
Here's Why 'Trend' Investors Would Love Betting on Zai Lab Limited (ZLAB)
Zai Lab Limited (ZLAB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade
The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website.
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC). “Receiving an Orphan Drug Designation for ZL-1310 recognizes its potential to treat patients with SCLC. These patients have an urgent need for innovative treatment opt.
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults. “There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited efficacy and undesirable side effects of current treatment options,” said Dr. Rafael Amado, M.D., Presiden.
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically meaningful improvement in overall survival with TIVDAK treatment for patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy. The China subpopulation results were consistent with those in the global population: TIVDAK demonstrate.
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
BOSTON & SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and.
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
SHANGHAI & CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and.
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
SHANGHAI & SUZHOU, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink's TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Through this collaboration, Zai Lab further expands its global oncology pipeline with anoth.
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the Chinese market, with key products like Zejula, Qinlock, Nuzyra, Vyvgart, and Optune driving revenue. Despite high costs, ZLAB's consistent quarterly revenue growth and a strong cash position indicate a promising future.
Zai Lab Announces Participation in Investor Conference in January 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conference in January 2025: 43rd Annual J.P. Morgan Healthcare Conference Presentation: Tuesday, January 14, 2025, 1:30 p.m. PST Location: San Francisco A live webcast of the presentation will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.com/webcasts-present.
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally adv.
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: AUGTYRO® (repotrectinib) is included in the NRDL for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC); NUZYRA® (omadacycline) is ren.
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization inf.
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the anticipated closing of its previously announced underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. In addition, Zai Lab today announced that the underwriters in the offering fully exercis.
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. The gross proceeds to Zai Lab from the offering, before deducting underwriting discounts and commissions and other offeri.
Zai Lab Announces Proposed Public Offering of American Depositary Shares
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $200.0 million of American depositary shares (“ADSs”), each representing ten ordinary shares of the Company with a par value of $0.000006 per share. All ADSs will be offered by Zai Lab. Zai Lab expects to grant the underwriters a 30-day option to p.
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado – President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citigroup Operator Hello, ladies and gentlemen. Thank you for standing by.
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate updates. “In the third quarter, we delivered strong commercial results, maintained financial discipline, and continued to advance our global pipeline of innovative medicines,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “The launch of VYVGART® has been a.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ZLAB.